Abstract 246P
Background
Despite various awareness programmes and strict regulations for consumption of tobacco and alcohol, the incidence of oral cavity cancer is increasing in low and middle income countries. We have reported here clinico-epidemiological profile of 343 oral cavity cancer patients. Although, treatment guidelines exist, treatment failure is seen in more than 50% of patients.
Methods
We retrospectively analysed the data of 343 oral cavity cancer patients who reported to our department during 2010-2015. Detailed history and clinical examination followed by requisite investigations were done and treatment was given as per the existent guidelines.
Results
Out of 343 patients, 283 (82.5%) were males while 60 (17.4%) were females with a male: female ratio of 4.7:1. The mean and median age for the cohort was 46.2 yrs and 45 yrs, respectively. More patients presented in the age group of 31-40 yrs (29.4%) and 41-50 yrs (27.4%). The youngest patient was 21 yrs while the oldest was 85 yrs. Tongue was the most common site of involvement followed by buccal mucosa. Histopathologically, tumours with moderate differentiation were most frequent followed by well differentiated. Approximately, 60% patients underwent surgery with or without adjuvant radiation. Remaining 40% cases, for whom surgery could not be done, received definitive radiation. Overall, however, 40% of cases had treatment failure despite aggressive multimodality treatment with local recurrence observed in more than half. Locoregional recurrence occurred in 19.1% while disease metastasized to distant areas in 8.8% cases.
Conclusions
Our study provided a clinico-epidemiological profile and failure rates of patients having oral cavity cancers in North India. We have tried to study various risk factors associated with the disease. Significant number of patients presents very late in our setting and so failure rates are unacceptably high. Hence, there is a need to study various therapies for effective management without adding any significant financial burden on patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03